Saturday, March 23, 2013

Engineered immune cells battle acute leukaemia

The results of the trial — done in five patients with acute lymphoblastic leukaemia — are published in Science Translational Medicine1 and represent the latest success for a 'fringe' therapy in which a type of immune cell called T cells are extracted from a patient, genetically modified, and then reinfused back. In this case, the T cells were engineered to express a receptor for a protein on other immune cells, known as B cells, found in both healthy and cancerous tissue. 

Read more
Engineered immune cells battle acute leukaemia : Nature News & Comment


















Source: Nature

Art and Science of Laboratory Medicine

Twitter: LaboratoryEQAS
at

No comments:

Post a Comment